Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline topical loperamide

Executive Summary

Licensing agreement signed with Adolor for worldwide (excluding Korea) prescription and OTC development and commercial rights to topical dermal loperamide product ADL 2-1294 for use in the treatment of inflammatory pain, itching and other undisclosed indications. Adolor will receive an up-front payment and up to $48 mil. from development milestone payments. ADL 2-1294 lacks the CNS side effects associated with other narcotic opioids because it does not cross the blood-brain barrier, Adolor says, making it the only opioid drug that is not in a DEA controlled-drug schedule
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034609

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel